ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,761.00
0.77%
S&P ASX All Technology
3,066.90
-0.26%
Brent Oil
78.305
-3.09%
US Dollar vs AUD
1.49814
-0.03%
Bitcoin
68,932.00
1.74%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. MIRA Pharmaceuticals Inc (MIRA)

  7. MIRA Pharmaceuticals Inc (MIRA) News

MIRA

MIRA Pharmaceuticals (MIRA)

MIRA Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MIRA
DateTimeSourceHeadlineSymbolCompany
31/05/202408:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
29/05/202422:45PR Newswire (US)Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled SubstanceNASDAQ:MIRAMIRA Pharmaceuticals Inc
29/05/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
23/05/202407:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
21/05/202422:45PR Newswire (US)MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
20/05/202422:00PR Newswire (US)Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
14/05/202406:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRAMIRA Pharmaceuticals Inc
02/04/202423:00PR Newswire (US)Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND SubmissionNASDAQ:MIRAMIRA Pharmaceuticals Inc
22/03/202402:04PR Newswire (US)MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific AdvisorNASDAQ:MIRAMIRA Pharmaceuticals Inc
08/03/202408:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
06/02/202400:30PR Newswire (US)MIRA Pharmaceuticals Provides Corporate UpdateNASDAQ:MIRAMIRA Pharmaceuticals Inc
18/01/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
28/12/202316:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MIRAMIRA Pharmaceuticals Inc
28/12/202309:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
28/12/202309:27Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
19/12/202308:50Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MIRAMIRA Pharmaceuticals Inc
05/12/202300:00PR Newswire (US)MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence SimulationsNASDAQ:MIRAMIRA Pharmaceuticals Inc
02/12/202309:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
30/11/202300:00PR Newswire (US)MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%NASDAQ:MIRAMIRA Pharmaceuticals Inc
22/11/202302:42PR Newswire (US)MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
22/11/202302:09PR Newswire (US)MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1aNASDAQ:MIRAMIRA Pharmaceuticals Inc
21/11/202308:18Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
21/11/202308:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
21/11/202300:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
21/11/202300:00PR Newswire (US)MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2NASDAQ:MIRAMIRA Pharmaceuticals Inc
18/09/202322:30PR Newswire (US)MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than PotNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/09/202322:31PR Newswire (US)MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication EffortsNASDAQ:MIRAMIRA Pharmaceuticals Inc
31/08/202322:31PR Newswire (US)MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development SummitNASDAQ:MIRAMIRA Pharmaceuticals Inc
30/08/202301:39PR Newswire (US)MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
27/02/200909:42PR Newswire (US)MAC1 Industries Corp. Merges With Tycoon Industries, LLCNASDAQ:MIRA
 Showing the most relevant articles for your search:NASDAQ:MIRA

Your Recent History

ASX
BBX
BBX Minerals
BIT
DSUS
ETF
USOTC
STRG
Starguide (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved